Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-β family

BACKGROUND Primary pulmonary hypertension (PPH), resulting from occlusion of small pulmonary arteries, is a devastating condition. Mutations of the bone morphogenetic protein receptor type II gene (BMPR2), a component of the transforming growth factor beta (TGF-β) family which plays a key role in cell growth, have recently been identified as causing familial PPH. We have searched for BMPR2 gene mutations in sporadic PPH patients to determine whether the same genetic defect underlies the more common form of the disorder. METHODS We investigated 50 unrelated patients, with a clinical diagnosis of PPH and no identifiable family history of pulmonary hypertension, by direct sequencing of the entire coding region and intron/exon boundaries of the BMPR2 gene. DNA from available parent pairs (n=5) was used to assess the occurrence of spontaneous (de novo) mutations contributing to sporadic PPH. RESULTS We found a total of 11 different heterozygous germline mutations of theBMPR2 gene in 13 of the 50 PPH patients studied, including missense (n=3), nonsense (n=3), and frameshift (n=5) mutations each predicted to alter the cell signalling response to specific ligands. Parental analysis showed three occurrences of paternal transmission and two of de novo mutation of theBMPR2 gene in sporadic PPH. CONCLUSION The sporadic form of PPH is associated with germline mutations of the gene encoding the receptor protein BMPR-II in at least 26% of cases. A molecular classification of PPH, based upon the presence or absence ofBMPR2 mutations, has important implications for patient management and screening of relatives.

[1]  R. Trembath,et al.  Primary pulmonary hypertension: the pressure rises for a gene , 2000, Journal of clinical pathology.

[2]  N. Fretwell,et al.  A physical and transcript map based upon refinement of the critical interval for PPH1, a gene for familial primary pulmonary hypertension. The International PPH Consortium. , 2000, Genomics.

[3]  H. Lodish,et al.  Role of transforming growth factor beta in human disease. , 2000, The New England journal of medicine.

[4]  J. Massagué,et al.  Controlling TGF-β signaling , 2000, Genes & Development.

[5]  S. Hodge,et al.  Fine mapping of PPH1, a gene for familial primary pulmonary hypertension, to a 3-cM region on chromosome 2q33. , 2000, American journal of respiratory and critical care medicine.

[6]  H. Lodish,et al.  Role of Transforming Growth Factor in Human Disease , 2000 .

[7]  D. Marchuk Genetic abnormalities in hereditary hemorrhagic telangiectasia , 1998, Current opinion in hematology.

[8]  K. Miyazono,et al.  HNPCC associated with germline mutation in the TGF-β type II receptor gene , 1998, Nature Genetics.

[9]  K. Shroyer,et al.  Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. , 1998, The Journal of clinical investigation.

[10]  W. Edwards,et al.  Human immunodeficiency virus infection and pulmonary hypertension: two new cases and a review of 86 reported cases. , 1998, Mayo Clinic proceedings.

[11]  S. Hodge,et al.  Mapping of familial primary pulmonary hypertension locus (PPH1) to chromosome 2q31-q32. , 1997, Circulation.

[12]  N. D. Arnold,et al.  Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31–32 , 1997, Nature Genetics.

[13]  J. Benichou,et al.  Appetite-suppressant drugs and the risk of primary pulmonary hypertension , 1997 .

[14]  J Benichou,et al.  Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. , 1996, The New England journal of medicine.

[15]  M. Leppert,et al.  Coancestry in apparently sporadic primary pulmonary hypertension. , 1995, Chest.

[16]  V. Fuster,et al.  Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension. , 1993, British heart journal.

[17]  S. Rich,et al.  The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. , 1992, The New England journal of medicine.

[18]  T. N. James,et al.  Clinical and pathologic manifestations of pulmonary vascular disease in the toxic oil syndrome. , 1991, Journal of the American College of Cardiology.

[19]  B. Groves,et al.  Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. , 1989, Circulation.

[20]  R. Virmani,et al.  Heterogeneity of pathologic lesions in familial primary pulmonary hypertension. , 1988, The American review of respiratory disease.

[21]  D. Buff Primary pulmonary hypertension. , 1987, Annals of internal medicine.

[22]  E H Bergofsky,et al.  Primary pulmonary hypertension. A national prospective study. , 1987, Annals of internal medicine.

[23]  J. Newman,et al.  Familial primary pulmonary hypertension: clinical patterns. , 1984, The American review of respiratory disease.